In a report released yesterday, Vamil Divan from Mizuho Securities reiterated a Hold rating on Evolus (EOLS), with a price target of $5.00. The company’s shares closed last Wednesday at $3.67, close to its 52-week low of $2.85.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -0.8% and a 46.8% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
Evolus has an analyst consensus of Hold, with a price target consensus of $5.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.75 and a one-year low of $2.85. Currently, Evolus has an average volume of 451.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
